EdgeTestMarket TodayOptions TodayIPO
Start free

THYROCAREThyrocare Technologies Limited

Rs 470.65▲ +1.62%
Market closedEquity EOD 26 Oct
Compare
52-week rangeThe lowest and highest prices the stock traded at over the last year, from each day's intraday low and high. The marker is today's close: 0% means it sits at the year's low, 100% at the high. It describes where the price is, not where it is going.40.1% up the range
Rs 343Rs 662
THYROCARE price
Daily candles, adjusted for splits and bonus issues so a corporate action does not show as a crash. Pick a window from one month to the full history, add indicators, or open it full screen.
EOD 26 Oct
IndicatorsVolume

Loading THYROCARE price...

At a glance
Each figure is shown against the company's sector (the track: the dot is this company, the tick is the sector middle) and, where we hold the yearly filings, against its own recent years (the small trend line).
Market capWhat the whole company is worth on the stock market today: share price times the number of shares. It measures size, not quality.
Rs 7,491 cr
Larger than 62% of 8 peers
sector middle Rs 3,861 cr
P/EPrice to earnings: how many rupees investors pay for each rupee of profit the company made over the last twelve months. Compare it with similar companies rather than reading it alone.
27.6x
Lower than 60% of 5 peers
sector middle 44.8x
Price to bookPrice to book: the share price divided by the shareholders' money per share in the latest balance sheet. Around 1 means the market values the company close to its book value.
12.8x
Higher than 88% of 8 peers
sector middle 6.0x
ROEReturn on equity: the year's profit as a percentage of the shareholders' money in the business. It shows how much the company earns on what its owners have put in.
30.0%
Highest of 6 peers
sector middle 13.9%
FY23 12.0%FY26 27.8%
ROCEReturn on capital employed: operating profit as a percentage of all the long-term money in the business, owners' and lenders'. It shows how well the company uses its capital, whatever the mix of debt.
33.6%
Highest of 7 peers
sector middle 15.7%
FY23 16.1%FY26 33.6%
Debt to equityBorrowings divided by shareholders' money. 0 means no borrowings; 1 means it owes as much as its owners have put in. Not shown for banks and lenders, whose borrowing is their business.
0.00
No borrowings
sector middle 0.01
FY23 0.00FY26 0.00
Dividend yieldDividends paid over the last year as a percentage of the company's market value: roughly what Rs 100 of shares paid out in cash.
2.0%
Highest of 8 peers
sector middle 0.1%
Sales growthHow much the latest quarter's sales grew against the same quarter a year earlier.
+24.3%
Higher than 83% of 6 peers
sector middle +21.4%
FY23 -10.5%FY26 20.6%

Peers are the listed companies in the exchange's own industry group: Healthcare Service Provider. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

What the numbers say
Short lines written by fixed rules from the company's own filings and shareholding. A line appears only when the figures cross the rule (for example sales growing three years running), and each names the numbers behind it. Nothing here is a view on whether to own the share.

Latest quarterIn the quarter to June 2026 (results filed 23 Jul 2026), sales rose 24.3% from a year earlier to Rs 240 cr and profit rose 34.1% to Rs 51.3 cr.

Going well
  • Sales grew 3 years running (Rs 527 cr in FY23 to Rs 829 cr in FY26).
  • Profit grew 3 years running (Rs 64.3 cr in FY23 to Rs 163 cr in FY26).
  • Operating margin rose from 22.8% in FY23 to 31.6% in FY26.
  • No borrowings at the FY26 balance sheet.
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

How the share moved on results
For each quarterly result we hold: the change from the share's close on the last trading day before the filing to its close on the first trading day after it. Results can land during market hours or after the close, and this window covers both. It shows what happened, not what will happen next time.

Over the last 20 results, the share rose on 8 and fell on 12, and moved by 3% or more on 13.

Q1 FY23Q1 FY24Q1 FY25Q1 FY26Q1 FY27

Q1 FY27: results filed 23 Jul 2026. The share went from its close on 22 Jul 2026 to its close on 24 Jul 2026 +1.13%.

Where every Rs 100 of sales goes
From the company's own yearly results. Each year is scaled to that year's sales, so you compare shares, not size: how much went on running costs, depreciation, interest and tax, and how much was left as profit.
5 financial years
Sales, last 12 months
Rs 876 Cr
Profit, last 12 months
Rs 176 Cr
Earnings per share
Rs 17.0
Profit growth (qtr, YoY)
+34.06%

Of every Rs 100 of sales in FY26, Rs 68 went on running costs, Rs 7.1 on depreciation, Rs 0.3 on interest and Rs 6.0 on tax; Rs 20 was left as profit.

FY22
60
8.8
30
FY23
77
7.3
12
FY24
76
8.2
12
FY25
72
8.0
16
FY26
68
7.1
20
Sales (Rs 100)Other incomeRunning costsDepreciationInterestTaxProfitOther items

Thin bar: money in (sales plus other income). Thick bar: where it went. Each year is scaled to its own sales, so the bars compare shares, not size.

How fast it has grown
Compound growth per year in sales, profit and earnings per share between financial years, from the company's own results. A span appears only if our filings cover both ends of it.
Sales
3 yrs
+16.3%/yr
Latest qtr
+24.3%
Profit
3 yrs
+36.3%/yr
Latest qtr
+34.1%

Per year, compounded, between financial years FY26 and the year named; only spans our filings cover. The faint bar is the latest quarter against the same quarter a year earlier. Earnings per share is not shown: filed figures are not adjusted for bonus issues and splits, so its growth would mislead.

Health check, year by year
Margins, returns, debt and interest cover for each financial year. Each row is coloured against this company's own usual level, so you see what is improving and what is slipping.
MeasureFY22FY23FY24FY25FY26
Sales growthSales against the previous financial year.--10.5%8.6%20.2%20.6%
Operating marginProfit from operations, before depreciation, interest and tax, per Rs 100 of sales.39.9%22.8%24.0%27.7%31.6%
Net marginProfit after everything, per Rs 100 of sales.29.9%12.2%12.2%16.2%19.6%
ROEProfit as a percentage of shareholders' money (from the March balance sheet).-12.0%13.2%20.4%27.8%
ROCEOperating profit as a percentage of all long-term capital, owners' and lenders'.-16.1%18.0%26.3%33.6%
Debt to equityBorrowings divided by shareholders' money. Lower is safer.-0.00x0.04x0.00x0.00x
Interest coverHow many times operating profit covers the interest bill. Higher is safer.95.9x37.6x23.7x48.4x76.5x

Each row is coloured against this company's own usual level, not against other companies: green is better than its middle year, red worse, plain is close to it. ROE, ROCE and debt rows start once the filings carry a full balance sheet (FY22 at the earliest).

What it owns, and how that is paid for
Straight from the March balance sheet in the company's annual filing. Both bars are the whole balance sheet: what the company owns, and where the money for it came from.
as at 2026-03-31

At FY26 it owned Rs 747 Cr of assets. Its owners funded 78% of that, with no borrowings.

What it owns
28%
15%
20%
10%
9%
11%
Plant, property and projects209 Cr
Goodwill and intangibles112 Cr
Investments152 Cr
Inventory48 Cr
Owed by customers74 Cr
Cash and bank68 Cr
Everything else85 Cr
How that is paid for
78%
13%
Shareholders586 Cr
Owed to suppliers65 Cr
Other liabilities96 Cr
Cash and equivalents
Rs 38 Cr
Net debt
Rs -190 Cr
more cash than debt
Current ratio
3.39x
short-term assets per rupee due soon
Book value / share
Rs 37
Return on assets
23.5%
EV / EBITDA
26.8x

From the March balance sheet in the company's annual filing (2026-03-31). Each bar is the full balance sheet; "everything else" is what the filed total leaves after the named lines.

Where the cash went
Profit is an accounting figure; cash flow is what actually moved. Cash from running the business, plus or minus what was spent on or received from investments, plus or minus what came from or went to lenders and shareholders, equals the change in cash.

In FY26 the business itself brought in Rs 213 Cr, spent Rs 21 Cr on plant and equipment, and cash rose by Rs 21 Cr over the year.

From running the business
+213 Cr
Spent on or received from investing
-23 Cr
From or to lenders and shareholders
-170 Cr
Net change in cash
+21 Cr
Cash from operations for every Rs 100 of profit
Rs 201
FY23
Rs 241
FY24
Rs 211
FY25
Rs 131
FY26

Rs 100 or more means every rupee of reported profit arrived as cash.

Full financial year to 2026-03-31, from the company's cash flow statement.

Against its sector
Where this stock sits within its own sector on each measure. The marker is its position in the peer group and the notch is the sector median. A position is a fact about the cohort, not a view on the stock.
Healthcare Service Provider · 15
P/E27.62vs 44.82 median
Cheapest: KRSNAA 16.81Priciest: VIJAYA 76.73
Net margin20.08%vs 11.9% median
Lowest: HEALTHX -1.78%Highest: VIJAYA 21.87%
Revenue growth24.34%vs 21.4% median
Lowest: METROPOLIS 16.62%Highest: HEALTHX 49.73%
Compared against
3BBLACKBIOCHANDANCREDENTGAUDIUMIVFHEALTHXINVICTAKRSNAALALPATHLABMETROPOLISNEPHROPLUSNIDANONEGLOBALPRAMODINISURAKSHAVIJAYA

Median rather than average, so one loss-making or one very expensive peer cannot drag the reference. Valuation is shown without a colour verdict: a higher multiple can mean expensive, or faster growth expected, and only you can decide which.

Peers side by side
Every company in the same NSE industry group that we hold figures for, largest first. Tap any heading to sort by it. The same figures as the At a glance tiles, worked out the same way for every company.
Healthcare Service Provider · 9 shown
Company
LALPATHLAB
Dr. Lal Path Labs Ltd.
31,100 cr44.8x12.4x21.5%25.7%0.0018.9%+19.1%0.72%
VIJAYA
Vijaya Diagnostic Centre Limited
14,362 cr76.7x15.0x19.6%19.2%0.0021.9%+22.8%0.14%
METROPOLIS
Metropolis Healthcare Limited
10,989 cr22.8x7.3x13.3%15.7%0.0111.9%+16.6%0.19%
THYROCARE
Thyrocare Technologies Limited
7,491 cr27.6x12.8x30.0%33.6%0.0020.1%+24.3%1.98%
NEPHROPLUS
Nephrocare Health Services Limited
6,095 cr-5.5x-13.7%0.07--0.00%
SURAKSHA
Suraksha Diagnostic Limited
1,628 cr45.4x6.7x14.4%14.7%0.0110.8%+20.8%0.00%
KRSNAA
Krsnaa Diagnostics Limited
1,617 cr16.8x1.6x9.9%10.6%0.5511.9%+22.1%0.55%
HEALTHX
Health X Platform Limited
857 cr-1.3x-3.4%---1.8%+49.7%0.00%
GAUDIUMIVF
Gaudium IVF and Women Health Limited
674 cr-4.4x-23.1%0.15--0.00%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

The business
Sales and net profit from the company's own filings, by financial year or by quarter. Hover any bar for that period's complete figures including operating margin and the change against the comparable earlier period. The single TTM figure above is the sum of the last four quarters.
5 years · 20 quarters
Full financial years - the long arc of the business.
Sales growth
+16.3%
a year, 3 years
Profit growth
+36.3%
a year, 3 years
Operating margin
31.6%
latest year
Sales by financial yearRs 829 Cr
Net profit by financial yearRs 163 Cr
FY225 full years · hover a yearFY26

Operating margin has gone from 39.9% to 31.6% over these years - the share of every rupee of sales kept after running costs, before interest and tax. Full financial years only, so a part-year is never shown as a whole one. Hover any year for its complete figures.

Dividends paid
Cash paid per share, from the exchange's corporate-action record, restated to today's share count across bonuses and splits. Dates shown are ex-dates: you must own the shares before that date to receive the payment.
1.49% yield
Rs 1,490 / year
Paid 11 of 11 yrs
on Rs 1 lakh at today's price · 1.49% yield · Rs 7/share
What each year paid, on Rs 1 lakh
710
710
1,772
708
1,062
1,062
1,275
1,275
1,982
1,487
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid Rs 7.00 per share, about Rs 1,487 on Rs 1 lakh at today's price. Earlier years are restated to today's share count, so a bonus or split never reads as a dividend cut. Dividends are at the company's discretion and can be cut or skipped.

Large institutional deals
Bulk and block deals reported by the exchange, where a single large trade is disclosed along with the counterparty's name. Only deals above the exchange's disclosure threshold appear here.
last 8
DatePartySideQtyPriceValue
2026-08-13DOCON TECHNOLOGIES PRIVATE LIMITEDSELL1,31,68,657624Rs 821.72 Cr
2026-08-13DOCON TECHNOLOGIES PRIVATE LIMITEDSELL1,31,68,657624Rs 821.72 Cr
2026-08-13HSBC MUTUAL FUNDBUY29,99,731624Rs 187.18 Cr
2026-08-13HSBC MUTUAL FUNDBUY29,99,731624Rs 187.18 Cr
2026-08-13KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITEDBUY24,00,000624Rs 149.76 Cr
2026-08-13KOTAK MAHINDRA LIFE INSURANCE COMPANY LIMITEDBUY24,00,000624Rs 149.76 Cr
2026-08-13DSP MUTUAL FUNDBUY13,21,363624Rs 82.45 Cr
2026-08-13DSP MUTUAL FUNDBUY13,21,363624Rs 82.45 Cr
Technical snapshot
Momentum, trend and delivery-based conviction from the actual price and volume history.
EOD 26 Oct
RSI (14) - momentum
33.7Neutral
0 oversold3070overbought 100
Delivery % - genuine buying vs churn
52.6%Near average
today 52.6%20d avg 55.6%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50-DMA
-14.38%
vs 200-DMA
-3.14%
1-month
-17.97%
3-month
-16.59%
1-year
+10.68%
Realized vol (30d)
31.7%
Insider trading disclosures
Promoter, director and other insider trades in the company's own shares, as disclosed to the exchange under SEBI's insider-trading regulations - usually within a few days of the transaction.
last 18 months

Insider trading data unavailable.

Recent announcements
The company's own filings to the exchange - results, board meetings, investor calls - with a link to the source document.
last 6 months

Announcements unavailable.

Want to test a strategy on THYROCARE?

Backtest an equity strategy on real market data, free - no card needed.

Start free

Equity price, fundamentals and realized volatility are end-of-day / quarterly from real market data. The option chain (PCR, max pain, expected move, IV, OI) is live from the exchange during market hours; outside them it shows the last session's close. Shareholding, insider trades and announcements are the company's own exchange filings. Analysis only, not investment advice.